Biogen Inc (NASDAQ:BIIB)

230.88
Delayed Data
As of 4:00pm ET
 -3.01 / -1.29%
Today’s Change
217.10
Today|||52-Week Range
468.55
-3.77%
Year-to-Date
Ionis' (IONS) Partner to Begin New Huntington's Disease Study
Jan 18 / Zacks.com - Paid Partner Content
4 Biotech Acquisitions We'd Like to See in 2022
Jan 14 / MotleyFool.com - Paid Partner Content
Is Biogen a Buy After the Latest Aduhelm Disaster?
Jan 17 / MotleyFool.com - Paid Partner Content
Longleaf Partners Comments on Biogen
Jan 13 / GuruFocus News - Paid Partner Content
Where Will Biogen Be in 5 Years?
Jan 15 / MotleyFool.com - Paid Partner Content
Longleaf Partners Fund's 4th-Quarter Commentary
Jan 13 / GuruFocus News - Paid Partner Content
Biogen Inc. (BIIB) Outpaces Stock Market Gains: What You Should Know
Jan 14 / Zacks.com - Paid Partner Content
Why Biogen Stock Is Sinking Today
Jan 12 / MotleyFool.com - Paid Partner Content
Biogen Is More Likely to Be a Buyer Than Seller
Jan 14 / GuruFocus News - Paid Partner Content
Biogen (BIIB) Down on Medicare Draft Ruling for Alzheimer's Drugs
Jan 12 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close233.89
Today’s open234.35
Day’s range230.70 - 234.95
Volume66,334
Average volume (3 months)1,384,700
Market cap$35.2B
Data as of 4:00pm ET, 01/19/2022

Growth & Valuation

Earnings growth (last year)-21.00%
Earnings growth (this year)-42.95%
Earnings growth (next 5 years)-4.00%
Revenue growth (last year)-2.82%
P/E ratio22.1
Price/Sales3.20
Price/Book3.41

Competitors

----
BMRNBiomarin Pharmaceuti...-0.67-0.77%
TECHBio-Techne Corp+0.30+0.08%
EXASExact Sciences Corp-1.35-1.74%
Data as of 4:00pm ET, 01/19/2022

Financials

Next reporting dateJanuary 27, 2022
EPS forecast (this quarter)$3.34
Annual revenue (last year)$12.4B
Annual profit (last year)$4.0B
Net profit margin32.38%

Profile

Sector
Health Technology
Industry
Biotechnology
No executives to display
Corporate headquarters
Cambridge, Massachusetts

Forecasts